Abstract 385P
Background
Although systemic chemotherapy or concurrent chemoradiotherapy (CRT) are effective for HPV-positive oropharyngeal squamous carcinoma (OPSCC), for these reasons, de-escalation therapy can be suggested as an optional therapy. However, in clinical practice, de-escalation therapy for HPV-positive OPSCC is insufficient to apply to all patients considering risk factors such as smoking. Thus, we investigated the high-risk factors associated with the treatment outcomes.
Methods
Patients with stage III-IVA OPSCC (AJCC 8th) who were treated for induction chemotherapy followed by CRT between 2004 and 2020 were enrolled. We analyzed the overall response rate, 3-year disease-free survival (3Y DFS), and 5-year overall survival (5Y OS) which were associated with clinical factors, by univariate and multivariate analyses.
Results
In a total of 105 patients, HPV-negative patients accounted for 38.1% (40/105) and HPV-positive patients for 61.9% (65/105). The median age at diagnosis was 60 years (range, 40 to 76). In multivariate analysis, a poor prognosis was revealed by a statistically significant difference in the 3Y DFS estimate for the subset of patients with ≥60 years and T4 compared with those with <60 years and T0-T3. In HPV- negative OPSCC, N2c was a strong and independent factor for poor DFS (HR 6.01, 95% CI 1.209-29.871, p=0.028). Unlike HPV-negative OPSCC, in HPV-positive OPSCC, age≥60 (HR 2.802, 95% CI 1.113-7.051, p=0.029) and T4 (HR 3.531, 95% CI 1.300-9.589, p=0.013) were independent prognostic factors for poor DFS. Additionally, T4 was independent factors for poor OS (HR 4.587, 95% CI 1.334-15.772, p=0.016). In the context of risk factors, we observed that T4 was a strong and independent predictor of poor DFS and OS in patients with HPV-positive OPSCC.
Conclusions
In conclusion, our analysis represents independent poor prognosis factors with T4 in p16 -positive OPSCC. Therefore, de-escalation therapy should be carefully determined for HPV-positive OPSCC patients with risk factors, and additional therapeutic approaches such as induction chemotherapy could be considered.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
540P - Phase III study of serplulimab plus chemotherapy as first-line therapy for advanced squamous non-small cell lung cancer: ASTRUM-004 Asian subgroup
Presenter: Caicun Zhou
Session: Poster Display
Resources:
Abstract
541P - Integrated analysis of randomized controlled trials IMpower130 and IMpower132 for advanced non-squamous non-small cell lung cancer (NSCLC)
Presenter: Hibiki Udagawa
Session: Poster Display
Resources:
Abstract
542P - First-line HLX07 plus serplulimab with or without chemotherapy versus serplulimab plus chemotherapy in advanced/recurrent squamous non-small cell lung cancer: A phase II study
Presenter: Zhen Wang
Session: Poster Display
Resources:
Abstract
543P - A multicenter retrospective study to investigate risk factors for immune checkpoint inhibitor-induced pneumonitis in non-small cell lung cancer patients with comorbid interstitial pneumonia
Presenter: Yuriko Ishida
Session: Poster Display
Resources:
Abstract
544P - Single cell level investigation of blood cells representing immune checkpoint inhibitor response in lung adenocarcinoma patients
Presenter: Juyong Seong
Session: Poster Display
Resources:
Abstract
545P - Completion of pembrolizumab in advanced non-small cell lung cancer: Real-world outcomes after two years of therapy (COPILOT)
Presenter: Andrew Fantoni
Session: Poster Display
Resources:
Abstract
546P - Combination therapy with anti-PD-1 antibody plus angiokinase inhibitor exerts synergistic antitumor effect against malignant mesothelioma via tumor microenvironment modulation
Presenter: Akio Tada
Session: Poster Display
Resources:
Abstract
547P - Immunotherapy outcome in advanced/metastatic lung cancer patients in real-world experience: Indian data
Presenter: Naveen K
Session: Poster Display
Resources:
Abstract
548P - B-Myb acts as a mentor instant promoter in non-small cell lung cancer by modifying the PD-1/PD-L1 axis
Presenter: Pan Xu
Session: Poster Display
Resources:
Abstract
549P - Drug-induced interstitial lung disease in patients with non-small cell lung cancer treated with immunotherapy for postoperative recurrence: Evaluation of CT findings and histopathological findings of the background lung
Presenter: shodai fujimoto
Session: Poster Display
Resources:
Abstract